| | | | |
CUSIP No. 24661P807 | | 13D | | Page 3 of 6 Pages |
Item 1. Security and Issuer
This Statement on Schedule 13D (this “Schedule 13D”) relates to shares of the common stock, par value $0.01 per share (the “Common Stock”), of Delcath Systems, Inc., a Delaware corporation (the “Company” or the “Issuer”), whose principal executive offices are located at 1633 Broadway, Suite 22C, New York, New York 10019.
Item 2. Identity and Background.
| (a) | This Schedule 13D is being filed by Gerard Michel (the “Reporting Person”). |
| (b) | The business address of the Reporting Person is c/o Delcath Systems, Inc., 1633 Broadway, Suite 22C, New York, New York 10019. |
| (c) | The Reporting Person is an individual presently employed as the Chief Executive Officer of the Company. |
| (d) | The Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years. |
| (e) | During the last five years, the Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting, or mandating activities subject to, United States federal or state securities laws or finding any violation with respect to such laws. |
| (f) | The Reporting Person is a citizen of the United States. |
Item 3. Source and Amount of Funds or Other Consideration.
The shares of Common Stock to which this Schedule 13D relates have been purchased by the Reporting Person in cash using the Reporting Person’s personal funds.
Item 4. Purpose of Transaction.
On July 18, 2022, the Company and certain accredited investors, including the Reporting Person, entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company agreed to sell and issue to the investors in a private placement (the “Private Placement”): (i) an aggregate of 690,954 shares of Common Stock at a purchase price of $3.98 per share and (ii) in lieu of shares of Common Stock, 566,751 pre-funded warrants to purchase Common Stock at a purchase price of $3.97 per pre-funded warrant, which pre-funded warrants have an exercise price of $0.01 per share of Common Stock and are immediately exercisable and remain exercisable until exercised in full. The Reporting Person purchased and was issued 62,814 shares of Common Stock in the Private Placement, which closed on July 20, 2022.
In connection with the Private Placement, the Company and the investors entered into a registration rights agreement dated July 18, 2022 (the “Registration Rights Agreement”), providing for the registration for resale of the securities (including the shares of Common Stock underlying the pre-funded warrants) issued under the Securities Purchase Agreement that are not then registered on an effective registration statement, pursuant to a registration statement to be filed with the Securities and Exchange Commission on or prior to September 16, 2022.
3